Candesartan cilexetil
Atacand (candesartan cilexetil) is a small molecule pharmaceutical. Candesartan cilexetil was first approved as Atacand on 1998-06-04. It is used to treat diabetic nephropathies, heart failure, hypertension, and left ventricular dysfunction in the USA. It is known to target type-1 angiotensin II receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| cardiovascular diseases | D002318 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Atacand (generic drugs available since 2012-12-04)
CombinationsAtacand (generic drugs available since 2012-12-04)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| atacand | New Drug Application | 2020-06-19 |
| candesartan cilexetil | ANDA | 2023-01-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| diabetic nephropathies | EFO_0000401 | D003928 | — |
| heart failure | EFO_0003144 | D006333 | I50 |
| hypertension | EFO_0000537 | D006973 | I10 |
| left ventricular dysfunction | — | D018487 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C09: Agents acting on the renin-angiotensin system
— C09C: Angiotensin ii receptor blockers (arbs), plain
— C09CA: Angiotensin ii receptor blockers (arbs), plain
— C09CA06: Candesartan
— C09D: Angiotensin ii receptor blockers (arbs), combinations
— C09DA: Angiotensin ii receptor blockers (arbs) and diuretics
— C09DA06: Candesartan and diuretics
— C09DB: Angiotensin ii receptor blockers (arbs) and calcium channel blockers
— C09DB07: Candesartan and amlodipine
— C09DX: Angiotensin ii receptor blockers (arbs), other combinations
— C09DX06: Candesartan, amlodipine and hydrochlorothiazide
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | 3 | — | 3 | 7 |
| Bronchopulmonary dysplasia | D001997 | P27.8 | 1 | 2 | 2 | — | 1 | 5 | |
| Acute lung injury | D055371 | EFO_0004610 | — | 1 | 1 | — | — | 1 | |
| Lung transplantation | D016040 | — | 1 | 1 | — | — | 1 | ||
| Primary graft dysfunction | D055031 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bronchiolitis | D001988 | HP_0011950 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CANDESARTAN CILEXETIL |
| INN | candesartan |
| Description | Candesartan is a benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension. It has a role as an antihypertensive agent, an angiotensin receptor antagonist, an environmental contaminant and a xenobiotic. It is a benzimidazolecarboxylic acid and a biphenylyltetrazole. It is a conjugate acid of a candesartan(2-). |
| Classification | Small molecule |
| Drug class | angiotensin II receptor antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 139481-59-7 |
| RxCUI | 214354 |
| ChEMBL ID | CHEMBL1014 |
| ChEBI ID | 3348 |
| PubChem CID | 2541 |
| DrugBank | DB13919 |
| UNII ID | S8Q36MD2XX (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
AGTR1
AGTR1
Organism
Homo sapiens
Gene name
AGTR1
Gene synonyms
AGTR1A, AGTR1B, AT2R1, AT2R1B
NCBI Gene ID
Protein name
type-1 angiotensin II receptor
Protein synonyms
Angiotensin II type-1 receptor, AT1 receptor, AT1AR, AT1BR, type-1B angiotensin II receptor
Uniprot ID
Mouse ortholog
Agtr1b (11608)
type-1 angiotensin II receptor B (P29755)
Variants
Clinical Variant
No data
Financial
Atacand - AstraZeneca
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,175 documents
View more details
Safety
Black-box Warning
Black-box warning for: Atacand, Candesartan cilexetil
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
102 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more